Today the TSC Alliance® applauds the U.S. Food and Drug Administration’s (FDA’s) approval of HYFTOR™, which is the first FDA-approved topical treatment for facial angiofibromas in adults and children six years of age or older who have tuberous sclerosis complex (TSC). HYFTOR™, manufactured by Nobelpharma America, LLC, has Orphan Drug Status for this particular indication. …
eTurboNews izindatshana ezababhalisi kuphela. Ukubhalisa kuyinto MAHHALA.
Ababhalisile bangena lapha Chofoza lapha ukuze ubhalise MAHHALA
Ababhalisile bangena lapha Chofoza lapha ukuze ubhalise MAHHALA
LOKHO ONGAKUTHATHE KULESI SIHLOKO:
- Food and Drug Administration’s (FDA’s) approval of HYFTOR™, which is the first FDA-approved topical treatment for facial angiofibromas in adults and children six years of age or older who have tuberous sclerosis complex (TSC).
- HYFTOR™, manufactured by Nobelpharma America, LLC, has Orphan Drug Status for this particular indication.
- eTurboNews izindatshana ezababhalisi kuphela.
